- In July 2022, Incyte Corporation (U.S.) announced that the U.S. FDA approved Opzelura (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in patients aged 12 years and older. This approval marks the first and only FDA-approved therapy that offers repigmentation benefits in vitiligo, representing a significant advancement in dermatologic treatment. Opzelura leverages Janus kinase (JAK) inhibition to target the underlying immune mechanisms of vitiligo, offering new hope to patients affected by this chronic autoimmune skin disorder
- In July 2022, the U.S. Food and Drug Administration approved the first topical treatment specifically indicated for repigmentation in patients with vitiligo aged 12 years and older. The approval of ruxolitinib cream 1.5% (marketed as Opzelura by Incyte) provides a targeted, non-invasive therapeutic option for individuals suffering from nonsegmental vitiligo, helping address a significant unmet medical need and improving quality of life for affected patients
